French health authorities have suspended the use of Valneva’s chikungunya vaccine Ixchiq in adults aged 65 and older after ...

In the evening of April 22, Valneva will attend the Vaccine Industry Excellence Awards ceremony, where it is a finalist for the Best Biotech Award and Best Prophylactic Vaccine Award for VLA15, the ...

Shares of French speciality vaccines developer Valneva (Nasdaq: VAL) were down 8.4% at 2.89 euros by early afternoon, after ...

An aide to U.S. Health Secretary Robert F. Kennedy Jr. is seeking more information about three vaccines recommended by a ...

Shares in Valneva plunged after the company said France's health authorities suspended the use of its chikungunya vaccine, Ixchiq, for people aged 65 and older, raising concerns about the vaccine's ...

Valneva has received marketing authorisation from the Brazilian Health Regulatory Agency (ANVISA) for its single-dose chikungunya vaccine, Ixchiq, for individuals aged 18 years and above.

Valneva has been responding to the French government’s call for vaccine supply of IXCHIQ® in La Reunion1 as the island is going through a major chikungunya outbreak with ~ 40,000 confirmed ...

The country is considered the epicenter of the disease in the Americas, with epidemics reported over the years.

As safety flags hang over Valneva’s chikungunya vaccine in the U.S. and beyond, French authorities are clamping down on the shot’s use in older adults. | France’s public health agency has temporarily ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that France’s national public health agency, the Haute Autorité de Santé (HAS), has updated its ...